Atypical femoral fractures

Published on October 31, 2016   31 min

Other Talks in the Series: Bone in Health and Disease

Please wait while the transcript is being prepared...
I'm Angela Cheung from Toronto, Canada, and I am going to discuss Atypical Femoral Fractures today.
These are my disclosures. I have received honoraria from, for CME events and/or grants to my institution from these companies. And I've also been a member of the ASBMR International Task Force on Atypical Femoral Fractures, as well as the Osteoporosis Canada Guidelines on the Diagnosis, Management, and Prevention of Atypical Femoral Fractures.
I'm going to discuss the definition, epidemiology, clinical risk factors, diagnosis and management, and prevention of atypical femoral fractures.
Right now in osteoporosis, these are the pharmacological therapies, they are in Canada. The first line therapies are antiresorptive therapies with bisphosphonates, denosumab, raloxifene, and estrogen in menopausal women with symptoms as well as bone formation therapy, and we only have one, it's called teriparatide. These therapies have been shown to reduce vertebral fracture, hip fractures, and non-vertebral fractures as you can see on the slide based on randomized control trials.
They've also been shown, especially the antiresorptive therapies with bisphosphonates and denosumab in a meta-analysis done by Bolland, they have been shown to reduce mortality as well. The relative risk here of 0.89 is statistically significant.